Welcome to Hodoodo Chemicals

Zolmitriptan
featured

WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318997

CAS#: 139264-17-8

Description: Zolmitriptan is a member of the triptan class agents with anti-migraine property. Zolmitriptan selectively binds to and activates serotonin (5-HT) 1B expressed in intracranial arteries and 5_HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brain stem sensory nuclei. Receptor binding results in constriction of cranial vessels, reduction of the vessel pulsation and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Zolmitriptan may also relief migraine headaches by inhibition pro-inflammatory neuropeptide release.

Chemical Structure

Zolmitriptan

CAS# 139264-17-8

Instruction

Theoretical Analysis

Hodoodo Cat#: H318997
Name: Zolmitriptan
CAS#: 139264-17-8
Chemical Formula: C16H21N3O2
Exact Mass: 287.16
Molecular Weight: 287.363
Elemental Analysis: C, 66.88; H, 7.37; N, 14.62; O, 11.14

Price and Availability

Size	Price	Availability
1g	USD 250	2 Weeks
2g	USD 450	2 Weeks
5g	USD 950	2 Weeks
10g	USD 1650	2 Weeks
20g	USD 2950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. Hodoodo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: 311C90; Zolmitriptan; NSC 760383; NSC-760383; NSC760383;

IUPAC/Chemical Name: (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one

InChi Key: ULSDMUVEXKOYBU-ZDUSSCGKSA-N

InChi Code: InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1

SMILES Code: O=C1OC[C@H](CC2=CC3=C(NC=C3CCN(C)C)C=C2)N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 287.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014 May 21;5:CD008616. doi: 10.1002/14651858.CD008616.pub2. Review. PubMed PMID: 24848613.

2: Tepper SJ, Chen S, Reidenbach F, Rapoport AM. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013 Sep;53 Suppl 2:62-71. doi: 10.1111/head.12181. Review. PubMed PMID: 24024604.

3: Peterlin BL, Rapoport AM. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):899-911. Review. PubMed PMID: 18028032.

4: Pacheco-Coronado R, McMullan PW, Galbut BH, Galbut EJ, Snell J, Schaer GL, Kavinsky CJ. Myocardial infarction after taking zolmitriptan. Yale J Biol Med. 2005 May;78(3):147-50. Review. PubMed PMID: 16464313; PubMed Central PMCID: PMC2259142.

5: Goadsby PJ, Yates R. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache. 2006 Jan;46(1):138-49. Review. PubMed PMID: 16412161.

6: Dowson AJ, Almqvist P. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin. 2005;21 Suppl 3:S13-7. Review. PubMed PMID: 16083519.

7: Gawel M, Worthington I. Intranasal zolmitriptan. Expert Opin Pharmacother. 2005 Jun;6(6):1019-24. Review. PubMed PMID: 15952929.

8: Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Zolmitriptan (Zomig). Expert Rev Neurother. 2004 Jan;4(1):33-41. Review. PubMed PMID: 15853613.

9: Boutilier AS, Gardner DM. Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report. J Clin Pharm Ther. 2003 Feb;28(1):69-72. Review. PubMed PMID: 12605621.

10: Goadsby PJ, Boes CJ. Zolmitriptan: differences from sumatriptan. Curr Med Res Opin. 2001;17 Suppl 1:s46-50. Review. PubMed PMID: 12463277.

11: Dowson AJ, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother. 2002 Jul;3(7):993-1005. Review. PubMed PMID: 12083998.

12: Le Jeunne C. [Zolmitriptan]. Presse Med. 1999 Sep 25;28(28):1525-6. Review. French. PubMed PMID: 10526561.

13: Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in migraine. Drugs. 1999 Aug;58(2):347-74. Review. PubMed PMID: 10473025.

14: Morales Asín F. [Safety profile of 311C90 (zolmitriptan)]. Neurologia. 1998 Oct;13 Suppl 2:25-30. Review. Spanish. PubMed PMID: 9859692.

15: Leira R, Noya M. [Clinical efficacy of zolmitriptan in migraine]. Neurologia. 1998 Oct;13 Suppl 2:16-24. Review. Spanish. PubMed PMID: 9859691.

16: Pascual J. [Mechanism of action of zolmitriptan]. Neurologia. 1998 Oct;13 Suppl 2:9-15. Review. Spanish. PubMed PMID: 9859690.

17: Lipton RB, Stewart WF. Clinical applications of zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 Suppl 18:53-9. Review. PubMed PMID: 9399017.

18: Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 Suppl 18:21-7. Review. PubMed PMID: 9399014.

19: Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. Review. PubMed PMID: 9399012.

20: Mathew N. Zolmitriptan. Introduction. Cephalalgia. 1997 Oct;17 Suppl 18:1-3. Review. PubMed PMID: 9399011.

Your view history

Zolmitriptan featured